Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Attention Deficit and Disruptive Behavior Disorders

ClinicalTrials.gov lists 1,901 trials for Attention Deficit and Disruptive Behavior Disorders or a narrower condition beneath it. Eli Lilly and Company has the most among industry and government lead sponsors, with 53.

MeSH D019958 Mental Disorders F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 74 Phase 1/2 Phase 1/2 29 Phase 2 Phase 2 131 Phase 2/3 Phase 2/3 26 Phase 3 Phase 3 210 Phase 4 Phase 4 230 Not applicable Not applicable 852 Observational Observational 348 Phase 1 Phase 1 74 Phase 1/2 Phase 1/2 29 Phase 2 Phase 2 131 Phase 2/3 Phase 2/3 26 Phase 3 Phase 3 210 Phase 4 Phase 4 230 Not applicable Not applicable 852 Observational Observational 348

Trials per phase (log scale)

1 more section with rows

59 of the 1,901 trials are tagged with Attention Deficit and Disruptive Behavior Disorders itself; the rest are tagged with a narrower condition beneath it.

Get the Attention Deficit and Disruptive Behavior Disorders report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Attention Deficit and Disruptive Behavior Disorders trials start? (34)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 117

1990: 1 trials (Observational 1) 1991: 1 trials (Not applicable 1) 1995: 1 trials (Observational 1) 1996: 1 trials (Observational 1) 1997: 4 trials (Observational 1, Phase 4 1, Phase 3 2) 1998: 5 trials (Phase 4 1, Phase 3 2, Phase 2/3 1, Phase 1 1) 1999: 11 trials (Observational 5, Not applicable 2, Phase 4 2, Phase 3 2) 2000: 8 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 1/2 1) 2001: 11 trials (Observational 2, Not applicable 4, Phase 4 1, Phase 3 2, Phase 2 1, Phase 1 1) 2002: 13 trials (Observational 3, Not applicable 1, Phase 4 4, Phase 3 3, Phase 2 1, Phase 1 1) 2003: 29 trials (Observational 3, Not applicable 4, Phase 4 11, Phase 3 6, Phase 2/3 1, Phase 2 4) 2004: 44 trials (Observational 5, Not applicable 1, Phase 4 14, Phase 3 15, Phase 2/3 1, Phase 2 8) 2005: 62 trials (Observational 10, Not applicable 8, Phase 4 13, Phase 3 15, Phase 2/3 2, Phase 2 11, Phase 1/2 1, Phase 1 2) 2006: 59 trials (Observational 8, Not applicable 13, Phase 4 13, Phase 3 13, Phase 2 10, Phase 1/2 2) 2007: 61 trials (Observational 12, Not applicable 9, Phase 4 12, Phase 3 11, Phase 2/3 2, Phase 2 12, Phase 1/2 3) 2008: 73 trials (Observational 13, Not applicable 12, Phase 4 24, Phase 3 11, Phase 2/3 1, Phase 2 10, Phase 1/2 1, Phase 1 1) 2009: 65 trials (Observational 9, Not applicable 16, Phase 4 15, Phase 3 10, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 7) 2010: 69 trials (Observational 16, Not applicable 17, Phase 4 12, Phase 3 8, Phase 2/3 1, Phase 2 7, Phase 1/2 3, Phase 1 5) 2011: 61 trials (Observational 13, Not applicable 15, Phase 4 7, Phase 3 13, Phase 2/3 1, Phase 2 7, Phase 1/2 1, Phase 1 4) 2012: 77 trials (Observational 14, Not applicable 39, Phase 4 10, Phase 3 6, Phase 2/3 1, Phase 2 5, Phase 1 2) 2013: 66 trials (Observational 6, Not applicable 32, Phase 4 11, Phase 3 5, Phase 2 4, Phase 1/2 3, Phase 1 5) 2014: 87 trials (Observational 15, Not applicable 39, Phase 4 9, Phase 3 9, Phase 2/3 2, Phase 2 7, Phase 1/2 2, Phase 1 4) 2015: 78 trials (Observational 14, Not applicable 36, Phase 4 6, Phase 3 11, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 5) 2016: 92 trials (Observational 15, Not applicable 51, Phase 4 10, Phase 3 6, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 2) 2017: 68 trials (Observational 11, Not applicable 34, Phase 4 3, Phase 3 12, Phase 2 4, Phase 1 4) 2018: 90 trials (Observational 15, Not applicable 49, Phase 4 11, Phase 3 6, Phase 2 3, Phase 1/2 2, Phase 1 4) 2019: 87 trials (Observational 19, Not applicable 44, Phase 4 6, Phase 3 9, Phase 2 5, Phase 1/2 1, Phase 1 3) 2020: 63 trials (Observational 12, Not applicable 37, Phase 4 4, Phase 3 4, Phase 2 1, Phase 1/2 1, Phase 1 4) 2021: 84 trials (Observational 16, Not applicable 54, Phase 4 5, Phase 3 1, Phase 2/3 2, Phase 2 3, Phase 1 3) 2022: 99 trials (Observational 18, Not applicable 70, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 4) 2023: 105 trials (Observational 22, Not applicable 70, Phase 4 4, Phase 3 4, Phase 2/3 1, Phase 1 4) 2024: 117 trials (Observational 18, Not applicable 76, Phase 4 5, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 5) 2025: 104 trials (Observational 22, Not applicable 65, Phase 4 4, Phase 3 3, Phase 2/3 2, Phase 2 2, Phase 1/2 2, Phase 1 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 87
2025 104
2024 117
2023 105
2022 99
2021 84
2020 63
2019 87
2018 90
2017 68

Showing 10 of 34 earlier years.

Start your 14-day trial Email me all 34 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 100 trials starting in 2026 and about 100 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 157 trials still running at the 2026-10-09 snapshot; registered median of 20 months across 1,209 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Attention Deficit and Disruptive Behavior Disorders trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 74
Phase 1/2 29
Phase 2 131
Phase 2/3 26
Phase 3 210
Phase 4 230
Not applicable 852
Observational 348
Expanded access 1

How many Attention Deficit and Disruptive Behavior Disorders trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 63
Recruiting 183
Enrolling by invitation 23
Active, not recruiting 42
Completed 1,217

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Attention Deficit and Disruptive Behavior Disorders trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Eli Lilly and Company 53
Shire 47
National Institute of Mental Health (NIMH) 21
Otsuka Pharmaceutical Development & Commercialization, Inc. 21
Supernus Pharmaceuticals, Inc. 21

Which drugs are being tested for Attention Deficit and Disruptive Behavior Disorders? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
METHYLPHENIDATE 185
Lisdexamfetamine Dimesylate 51
Centanafadine 12
SPN-812 12
Dextroamphetamine 9

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Atomoxetine arm 102
Treatment As Usual 28
OROS Methylphenidate 16
Guanfacine Hydrochloride XR 15
fatty acids, omega-3 10

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Attention Deficit and Disruptive Behavior Disorders trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Syncope 32 17
Appendicitis 30 17
Suicidal ideation 30 13
Aggression 21 9
Concussion 16 11

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Attention Deficit and Disruptive Behavior Disorders? (236)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Novel Smartphone App and Supportive Accountability for the Treatment of Childhood Disruptive Behavior Problems: Protocol for a Randomized Controlled Trial. JMIR research protocols 2025 Yes
The longitudinal impact of an evidence-based multiple family group intervention (Amaka Amasanyufu) on oppositional defiant disorder and impaired functioning among children in Uganda: analysis of a cluster randomized trial from the SMART Africa-Uganda scale-up study (2016-2022). Journal of child psychology and psychiatry, and allied disciplines 2022 Yes
The Clinician Affective Reactivity Index: Validity and Reliability of a Clinician-Rated Assessment of Irritability. Behavior therapy 2020 Yes
Young Children with Attention-Deficit/Hyperactivity Disorder and/or Disruptive Behavior Disorders Are More Frequently Prescribed Alpha Agonists Than Stimulants. Journal of child and adolescent psychopharmacology 2020 Yes
Exposure-Based Cognitive-Behavioral Therapy for Disruptive Mood Dysregulation Disorder: An Evidence-Based Case Study. Behavior therapy 2020 Yes

Showing 5 of 236 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages